{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:20:07Z","timestamp":1783488007913,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to produce evidence on quality of life (QoL) among Italian growth hormone deficiency (GHD) children and adolescents treated with growth hormone (GH) and their parents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A survey was conducted among Italian children and adolescents aged 4\u201318 with a confirmed diagnosis of GHD and treated with GH therapy and their parents. The European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L) and the Quality of Life in Short Stature Youth (QoLISSY) questionnaires were administered between May and October 2021 through the Computer-Assisted Personal Interview (CAPI) method. Results were compared with national and international reference values.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The survey included 142 GHD children\/adolescents and their parents. The mean EQ-5D-3L score was 0.95 [standard deviation (SD) 0.09], while the mean visual analogue scale (VAS) score was 86.2 (SD 14.2); the scores are similar to those of a reference Italian population aged 18\u201324 of healthy subjects. As for the QoLISSY child-version, compared to the international reference values for GHD\/ idiopathic short stature (ISS) patients, we found a significantly higher score for the physical domain, and lower scores for coping and treatment; compared to the specific reference values for GHD patients, our mean scores were significantly lower for all domains except the physical one. As for the parents, we found a significantly higher score for the physical domain, and a lower score for treatment; compared to reference values GHD-specific, we found lower score in the social, emotional, treatment, parental effects, and total score domains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggest that the generic health-related quality of life (HRQoL) in treated GHD patients is high, comparable to that of healthy people. The QoL elicited by a disease specific questionnaire is also good, and comparable with that of international reference values of GHD\/ISS patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02106-3","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T09:02:25Z","timestamp":1684573345000},"page":"2513-2523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey"],"prefix":"10.1007","volume":"46","author":[{"given":"M.","family":"Maghnie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-1202","authenticated-orcid":false,"given":"M.","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Polistena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pozzobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"d\u2019Angela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Spandonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"issue":"10","key":"2106_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-021-00539-5","volume":"17","author":"C Hage","year":"2021","unstructured":"Hage C, Gan HW, Ibba A, Patti G, Dattani M, Loche S et al (2021) Advances in differential diagnosis and management of growth hormone deficiency in children. Nat Rev Endocrinol 17(10):608\u2013624","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2106_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.beem.2016.11.012","volume":"30","author":"N Improda","year":"2016","unstructured":"Improda N, Capalbo D, Esposito A, Salerno M (2016) Muscle and skeletal health in children and adolescents with GH deficiency. Best Pract Res Clin Endocrinol Metab 30(6):771\u2013783","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2106_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"86","author":"A Grimberg","year":"2016","unstructured":"Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB et al (2016) Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 86(6):361\u2013397","journal-title":"Horm Res Paediatr"},{"key":"2106_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2021.101392","volume":"57\u201358","author":"P Backeljauw","year":"2021","unstructured":"Backeljauw P, Cappa M, Kiess W, Law L, Cookson C, Sert C et al (2021) Impact of short stature on quality of life: a systematic literature review. Growth Horm IGF Res 57\u201358:101392","journal-title":"Growth Horm IGF Res"},{"key":"2106_CR5","unstructured":"Bettini A, Teodori C, Maffei F, Ciofi D, Stagi S, editors (2019) The experience of pain in children with Growth Hormone Deficiency and psychosocial correlates: preliminary data from a longitudinal prospective study. In: Hormone Research in Paediatrics Conference: 58th Annual Meeting of the European Society for Paediatric Endocrinology: ESPE"},{"issue":"2","key":"2106_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264403","volume":"17","author":"M Orso","year":"2022","unstructured":"Orso M, Polistena B, Granato S, Novelli G, Di Virgilio R, La Torre D et al (2022) Pediatric growth hormone treatment in Italy: a systematic review of epidemiology, quality of life, treatment adherence, and economic impact. PLoS ONE 17(2):e0264403","journal-title":"PLoS ONE"},{"issue":"10","key":"2106_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40618-017-0667-1","volume":"40","author":"J Quitmann","year":"2017","unstructured":"Quitmann J, Giammarco A, Maghnie M, Napoli F, Di Giovanni I, Carducci C et al (2017) Validation of the Italian Quality of Life in Short Stature Youth (QoLISSY) questionnaire. J Endocrinol Invest 40(10):1077\u20131084","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2106_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jval.2013.04.008","volume":"16","author":"L Scalone","year":"2013","unstructured":"Scalone L, Cortesi PA, Ciampichini R, Belisari A, D\u2019Angiolella LS, Cesana G et al (2013) Italian population-based values of EQ-5D health states. Value Health 16(5):814\u2013822","journal-title":"Value Health"},{"key":"2106_CR9","unstructured":"Chaplin J (2013) Quality of life in short stature youth: the QoLISSY Questionnnaire user's manual"},{"key":"2106_CR10","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J, editors (2014) Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL)","DOI":"10.1007\/978-94-007-7596-1"},{"issue":"2","key":"2106_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000341151","volume":"78","author":"A Geisler","year":"2012","unstructured":"Geisler A, Lass N, Reinsch N, Uysal Y, Singer V, Ravens-Sieberer U et al (2012) Quality of life in children and adolescents with growth hormone deficiency: association with growth hormone treatment. Horm Res Paediatr 78(2):94\u201399","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"2106_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1586\/14737167.2013.847366","volume":"13","author":"N Silva","year":"2013","unstructured":"Silva N, Bullinger M, Quitmann J, Ravens-Sieberer U, Rohenkohl A, Qo LG (2013) HRQoL of European children and adolescents with short stature as assessed with generic (KIDSCREEN) and chronic-generic (DISABKIDS) instruments. Expert Rev Pharmacoecon Outcomes Res 13(6):817\u2013827","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"2106_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00431-010-1299-z","volume":"170","author":"MD Stephen","year":"2011","unstructured":"Stephen MD, Varni JW, Limbers CA, Yafi M, Heptulla RA, Renukuntla VS et al (2011) Health-related quality of life and cognitive functioning in pediatric short stature: comparison of growth-hormone-na\u00efve, growth-hormone-treated, and healthy samples. Eur J Pediatr 170(3):351\u2013358","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2106_CR14","first-page":"431","volume":"9","author":"C Stheneur","year":"2011","unstructured":"Stheneur C, Sznajder M, Taylor M, Chevallier B (2011) Experience of adolescence in patients treated with GH during childhood. Pediatr Endocrinol Rev PER 9(1):431\u2013440","journal-title":"Pediatr Endocrinol Rev PER"},{"issue":"1","key":"2106_CR15","first-page":"15","volume":"18","author":"T Tanaka","year":"2009","unstructured":"Tanaka T, Tai S, Morisaki Y, Tachibana K, Kambayashi Y, Chihara K et al (2009) Evaluation of quality of life in children with GH deficiency and idiopathic short stature using the child behavior checklist. Clin Pediatr Endocrinol Case Rep Clin Investig 18(1):15\u201322","journal-title":"Clin Pediatr Endocrinol Case Rep Clin Investig"},{"issue":"1","key":"2106_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12955-019-1118-9","volume":"17","author":"J Bloemeke","year":"2019","unstructured":"Bloemeke J, Silva N, Bullinger M, Witt S, D\u00f6rr HG, Quitmann J (2019) Psychometric properties of the quality of life in short statured youth (QoLISSY) questionnaire within the course of growth hormone treatment. Health Qual Life Outcomes 17(1):49","journal-title":"Health Qual Life Outcomes"},{"key":"2106_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1477-7525-11-76","volume":"11","author":"M Bullinger","year":"2013","unstructured":"Bullinger M, Quitmann J, Power M, Herdman M, Mimoun E, DeBusk K et al (2013) Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument. Health Qual Life Outcomes 11:76","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2106_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1515\/jpem-2018-0403","volume":"32","author":"C Drosatou","year":"2019","unstructured":"Drosatou C, Vlachopapadopoulou EA, Bullinger M, Quitmann J, Silva N, Salemi G et al (2019) Validation of the Greek version of the quality of life in short stature youth (QoLISSY) questionnaire. J Pediatr Endocrinol Metab JPEM 32(3):215\u2013224","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"issue":"9","key":"2106_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40618-019-01027-4","volume":"42","author":"J Quitmann","year":"2019","unstructured":"Quitmann J, Bloemeke J, D\u00f6rr HG, Bullinger M, Witt S, Silva N (2019) First-year predictors of health-related quality of life changes in short-statured children treated with human growth hormone. J Endocrinol Invest 42(9):1067\u20131076","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2106_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/cen.13944","volume":"90","author":"M Shemesh-Iron","year":"2019","unstructured":"Shemesh-Iron M, Lazar L, Lebenthal Y, Nagelberg N, Tenenbaum A, Ezra R et al (2019) Growth hormone therapy and short stature-related distress: a randomized placebo-controlled trial. Clin Endocrinol 90(5):690\u2013701","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2106_CR21","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/cpp.2146","volume":"25","author":"N Silva","year":"2018","unstructured":"Silva N, Bullinger M, Sommer R, Rohenkohl A, Witt S, Quitmann J (2018) Children\u2019s psychosocial functioning and parents\u2019 quality of life in paediatric short stature: the mediating role of caregiving stress. Clin Psychol Psychother 25(1):e107\u2013e118","journal-title":"Clin Psychol Psychother"},{"issue":"10","key":"2106_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40618-018-0850-z","volume":"41","author":"R Sommer","year":"2018","unstructured":"Sommer R, Bl\u00f6meke J, Bullinger M, Quitmann J (2018) The psychometric evaluation of the quality of life in short stature youth (QoLISSY) instrument for German children born small for gestational age. J Endocrinol Invest 41(10):1185\u20131191","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2106_CR23","first-page":"83","volume":"23","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Hasegawa T, Ozono K, Tanaka H, Kanzaki S, Yokoya S et al (2014) Effect of growth hormone treatment on quality of life in Japanese children with growth hormone deficiency: an analysis from a prospective observational study. Clin Pediatr Endocrinol Case Rep Clin Investig 23(3):83\u201392","journal-title":"Clin Pediatr Endocrinol Case Rep Clin Investig"},{"key":"2106_CR24","doi-asserted-by":"publisher","first-page":"S506","DOI":"10.1016\/j.jval.2020.08.601","volume":"23","author":"J Loftus","year":"2020","unstructured":"Loftus J, Quitmann J, Valluri SR, Pastrak A, Reiter L, Roland CL (2020) PDB4 Evaluation of Quality of life in PRE-pubertal children using the quality of life in short stature youth (QOLISSY) questionnaire, following 12 months of growth hormone treatment with either a weekly somatrogon or a daily genotropin injection schedule. Value in Health 23:S506","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"2106_CR25","doi-asserted-by":"publisher","first-page":"A674","DOI":"10.1210\/jendso\/bvab048.1374","volume":"5","author":"J Loftus","year":"2021","unstructured":"Loftus J, Quitmann J, Valluri S, Pastrak A, Reiter L, Roland C (2021) Comparison of quality of life responses from caregiver and children aged \u2265 7 years using the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire, following 12 months of growth hormone treatment with either a weekly somatrogon or a daily genotropin injection schedule. J Endocr Soc 5(Suppl 1):A674","journal-title":"J Endocr Soc"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02106-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02106-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02106-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:22:59Z","timestamp":1699464179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02106-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02106-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohamad Maghnie has received research support from Merck Serono, and Pfizer; has consulted for BioMarin, Merck Serono, Novo Nordisk, Pfizer, and Sandoz. Barbara Polistena has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestle\u00b4 HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, she received consulting fees from UCB. Gabriella Pozzobon has received research support from Merck Serono and has consulted for Merck Serono, Novo Nordisk, Pfizer, and Sandoz. Federico Spandonaro has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestle\u00b4 HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, he received consulting fees from Amgen. Simona Granato, Roberto Di Virgilio and Daria La Torre are employees of Pfizer. Mariacarolina Salerno has received research support from Merck Serono and has consulted for Merck Serono, Novo Nordisk, Pfizer, and Sandoz. She is an Editor of the Journal of Endocrinological Investigation. All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"A signed informed consent was not required from participants in this anonymous and voluntary questionnaire survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}